The Use of Variant Maps to Explore Domain-Specific Mutations of FGFR1. (October 2017)

• Record Type: Journal Article
• Authors: Lansdon, L.A.; Bernabe, H.V.; Nidey, N.; Standley, J.; Schnieders, M.J.; Murray, J.C.
• Other Names: Richman Joy M. guest-editor.; Schutte Brian C. guest-editor.
• Is Part Of: Journal of dental research. Volume 96:Number 11(2017)
• Page Start: 1339
• Page End: 1345
• Publication Date: 2017-10
• Subjects: craniofacial anomalies -- craniofacial biology/genetics -- genetics -- protein modeling -- Hartsfield syndrome -- clinical phenotypes; Dentistry -- Periodicals; Dentistry -- Social aspects -- Periodicals; Dentistry -- Periodicals; Research -- Periodicals; 617.6005
• DOI: 10.1177/0022034517726496
• Languages: English
• ISSNs: 0022-0345

Abstract

Here we describe the genotype-phenotype correlations of diseases caused by variants in Fibroblast Growth Factor Receptor 1 ( FGFR1 ) and report a novel, de novo variant in FGFR1 in an individual with multiple congenital anomalies. The proband presented with bilateral cleft lip and palate, malformed auricles, and bilateral ectrodactyly of his hands and feet at birth. He was later diagnosed with diabetes insipidus, spastic quadriplegia, developmental delay, agenesis of the corpus callosum, and enlargement of the third cerebral ventricle. We noted the substantial phenotypic overlap with individuals with Hartsfield syndrome, the rare combination of holoprosencephaly and ectrodactyly. Sequencing of FGFR1 identified a previously unreported de novo variant in exon 11 (p.Gly487Cys), which we modeled to determine its predicted effect on the protein structure. Although it was not predicted to significantly alter protein folding stability, it is possible this variant leads to the formation of nonnative intra- or intermolecular disulfide bonds. We then mapped this and other disease-associated variants to a 3-dimensional model of FGFR1 to assess which protein domains harbored the highest number of pathogenic changes. We observed the greatest number of variants within the domains involved in FGF binding and FGFR activation. To further explore the contribution of each variant to disease, we recorded the phenotype resulting from each FGFR1 variant to generate a series of phenotype-specific protein maps and compared our results to benign variants appearing in control databases. It is our hope that the use of phenotypic maps such as these will further the understanding of genetic disease in general and diseases caused by variation in FGFR1 specifically.